• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发性硬化性胆管炎患者与非原发性硬化性胆管炎患者胆汁磁共振波谱检测胆管癌

Detection of cholangiocarcinoma with magnetic resonance spectroscopy of bile in patients with and without primary sclerosing cholangitis.

作者信息

Albiin N, Smith I C P, Arnelo U, Lindberg B, Bergquist A, Dolenko B, Bryksina N, Bezabeh T

机构信息

Division of Radiology, Department for Clinical Science, Intervention and Technology, Karolinska Institute, Stockholm, Sweden.

出版信息

Acta Radiol. 2008 Oct;49(8):855-62. doi: 10.1080/02841850802220092.

DOI:10.1080/02841850802220092
PMID:18608012
Abstract

BACKGROUND

Early detection of cholangiocarcinoma (CC) is very difficult, especially in patients with primary sclerosing cholangitis (PSC) who are at increased risk of developing CC.

PURPOSE

To evaluate 1H magnetic resonance spectroscopy ((1)H-MRS) of bile as a diagnostic marker for CC in patients with and without PSC.

MATERIAL AND METHODS

The institutional review board approved the study, and all patients gave informed consent. Bile from 49 patients was sampled and investigated using 1H-MRS. MR spectra of bile samples from 45 patients (18 female; age range 22-87 years, mean age 57 years) were analyzed both conventionally and using computerized multivariate analysis. Sixteen of the patients had CC, 18 had PSC, and 11 had other benign findings.

RESULTS

The spectra of bile from CC patients differed from the benign group in the levels of phosphatidylcholine, bile acids, lipid, and cholesterol. It was possible to distinguish CC from benign conditions in all patients with malignancy. Two benign non-PSC patients were misclassified as malignant. The sensitivity, specificity, and accuracy were 88.9%, 87.1%, and 87.8%, respectively.

CONCLUSION

With 1H-MRS of bile, cholangiocarcinoma could be discriminated from benign biliary conditions with or without PSC.

摘要

背景

胆管癌(CC)的早期检测非常困难,尤其是在原发性硬化性胆管炎(PSC)患者中,他们患CC的风险增加。

目的

评估胆汁的1H磁共振波谱((1)H-MRS)作为有或无PSC患者CC的诊断标志物。

材料与方法

机构审查委员会批准了该研究,所有患者均签署了知情同意书。对49例患者的胆汁进行采样并使用1H-MRS进行研究。对45例患者(18例女性;年龄范围22 - 87岁,平均年龄57岁)胆汁样本的磁共振波谱进行了常规分析和计算机多变量分析。其中16例患者患有CC,18例患有PSC,11例有其他良性发现。

结果

CC患者胆汁的波谱在磷脂酰胆碱、胆汁酸、脂质和胆固醇水平上与良性组不同。在所有恶性肿瘤患者中能够区分CC与良性情况。两名良性非PSC患者被误分类为恶性。敏感性、特异性和准确性分别为88.9%、87.1%和87.8%。

结论

通过胆汁的1H-MRS,可以区分有或无PSC的胆管癌与良性胆道疾病。

相似文献

1
Detection of cholangiocarcinoma with magnetic resonance spectroscopy of bile in patients with and without primary sclerosing cholangitis.原发性硬化性胆管炎患者与非原发性硬化性胆管炎患者胆汁磁共振波谱检测胆管癌
Acta Radiol. 2008 Oct;49(8):855-62. doi: 10.1080/02841850802220092.
2
Diagnosis of biliary strictures in conjunction with endoscopic retrograde cholangiopancreaticography, with special reference to patients with primary sclerosing cholangitis.结合内镜逆行胰胆管造影术诊断胆管狭窄,特别提及原发性硬化性胆管炎患者。
Endoscopy. 2002 Nov;34(11):909-16. doi: 10.1055/s-2002-35298.
3
Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures.严重胆管狭窄患者血清胰蛋白酶原-2对胆管癌的检测效能增强
J Hepatol. 2007 Nov;47(5):677-83. doi: 10.1016/j.jhep.2007.05.017. Epub 2007 Jun 27.
4
Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders.尿蛋白质组分析可区分胆管癌与原发性硬化性胆管炎和其他良性胆道疾病。
Gut. 2013 Jan;62(1):122-30. doi: 10.1136/gutjnl-2012-302047. Epub 2012 May 12.
5
Screening and diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis.原发性硬化性胆管炎患者胆管癌的筛查与诊断
Rev Gastroenterol Disord. 2009 Spring;9(2):E41-7.
6
Cholangioscopic characterization of dominant bile duct stenoses in patients with primary sclerosing cholangitis.原发性硬化性胆管炎患者主要胆管狭窄的胆管镜特征
Endoscopy. 2006 Jul;38(7):665-9. doi: 10.1055/s-2006-925257. Epub 2006 Apr 27.
7
Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma.胆汁癌胚抗原水平是胆管癌的一个标志物。
Am J Surg. 1996 Jan;171(1):147-52; discussion 152-3. doi: 10.1016/S0002-9610(99)80090-7.
8
Utility of bile duct brushings for the early detection of cholangiocarcinoma in patients with primary sclerosing cholangitis.胆管刷检在原发性硬化性胆管炎患者胆管癌早期检测中的应用
J Clin Gastroenterol. 2006 Apr;40(4):336-41. doi: 10.1097/01.mcg.0000210102.82241.de.
9
[Cholangiocarcinoma in primary sclerosing cholangitis: "chronicle of a death foretold"?].[原发性硬化性胆管炎中的胆管癌:“一场事先张扬的死亡纪事”?]
Harefuah. 2003 Jun;142(6):421-5, 486.
10
Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study.原发性硬化性胆管炎患者肝胆癌的危险因素及临床表现:一项病例对照研究。
Hepatology. 1998 Feb;27(2):311-6. doi: 10.1002/hep.510270201.

引用本文的文献

1
Machine learning-driven prediction of immune checkpoint inhibitor responses against cholangiocarcinoma: a bile biopsy perspective.机器学习驱动的针对胆管癌的免疫检查点抑制剂反应预测:胆汁活检视角
Front Immunol. 2025 Jun 16;16:1614683. doi: 10.3389/fimmu.2025.1614683. eCollection 2025.
2
Interplay of Cardiometabolic Syndrome and Biliary Tract Cancer: A Comprehensive Analysis with Gender-Specific Insights.心血管代谢综合征与胆道癌的相互作用:一项具有性别特异性见解的综合分析。
Cancers (Basel). 2024 Oct 9;16(19):3432. doi: 10.3390/cancers16193432.
3
The Search for Risk, Diagnostic, and Prognostic Biomarkers of Cholangiocarcinoma and Their Biological and Clinicopathologic Significance.
胆管癌风险、诊断及预后生物标志物的探索及其生物学和临床病理意义
Am J Pathol. 2025 Mar;195(3):422-436. doi: 10.1016/j.ajpath.2024.06.013. Epub 2024 Aug 3.
4
Advancements in metabolomics research in benign gallbladder diseases: A review.代谢组学在胆囊良性疾病研究中的进展:综述。
Medicine (Baltimore). 2024 May 24;103(21):e38126. doi: 10.1097/MD.0000000000038126.
5
Molecular Biomarkers in Cholangiocarcinoma: Focus on Bile.胆管癌中的分子生物标志物:聚焦于胆汁。
Curr Top Med Chem. 2024;24(8):722-736. doi: 10.2174/0115680266290367240130054142.
6
Identification of a novel bile marker clusterin and a public online prediction platform based on deep learning for cholangiocarcinoma.基于深度学习的新型胆汁标志物簇蛋白和公共在线预测平台用于胆管癌的诊断。
BMC Med. 2023 Aug 8;21(1):294. doi: 10.1186/s12916-023-02990-9.
7
Research progress of bile biomarkers and their immunoregulatory role in biliary tract cancers.胆汁生物标志物及其在胆道肿瘤中的免疫调节作用的研究进展。
Front Immunol. 2022 Oct 28;13:1049812. doi: 10.3389/fimmu.2022.1049812. eCollection 2022.
8
Diagnosis Biomarkers of Cholangiocarcinoma in Human Bile: An Evidence-Based Study.人胆汁中胆管癌的诊断生物标志物:一项基于证据的研究。
Cancers (Basel). 2022 Aug 13;14(16):3921. doi: 10.3390/cancers14163921.
9
Novel approaches in search for biomarkers of cholangiocarcinoma.寻找胆管癌生物标志物的新方法。
World J Gastroenterol. 2022 Apr 21;28(15):1508-1525. doi: 10.3748/wjg.v28.i15.1508.
10
Biliary Strictures and Cholangiocarcinoma - Untangling a Diagnostic Conundrum.胆管狭窄与胆管癌——解开诊断难题
Front Oncol. 2021 Sep 30;11:699401. doi: 10.3389/fonc.2021.699401. eCollection 2021.